Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P60842
UPID:
IF4A1_HUMAN
Alternative names:
ATP-dependent RNA helicase eIF4A-1
Alternative UPACC:
P60842; B2R6L8; D3DTP9; J3QLC4; P04765; Q5U018; Q61516
Background:
Eukaryotic initiation factor 4A-I (eIF4A-I) functions as an ATP-dependent RNA helicase, integral to the eIF4F complex, facilitating mRNA binding to the ribosome. This action is crucial for unwinding RNA secondary structures in the 5'-UTR of mRNAs, enabling the small ribosomal subunit to efficiently bind and scan for the initiator codon.
Therapeutic significance:
Understanding the role of Eukaryotic initiation factor 4A-I could open doors to potential therapeutic strategies.